ABIRATERONE, DAROLUTAMIDE, DZR123, -, -, ABIRATERONE, DZR123, DAROLUTAMIDE
CDZR123C12101
Phase 2 small_molecule active
Quick answer
ABIRATERONE, DAROLUTAMIDE, DZR123, -, -, ABIRATERONE, DZR123, DAROLUTAMIDE for Metastatic hormone-sensitive prostate cancer is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Metastatic hormone-sensitive prostate cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active